Navigation Links
Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting
Date:9/14/2009

VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, Germany.

In order to assess the risk-benefit profile of pirfenidone in IPF patients, a comprehensive review of safety was conducted involving two Phase 3 trials (CAPACITY 1 and CAPACITY 2) and two open-label studies (RECAP and PIPF-002). RECAP is an on-going open-label extension study that enrolled 603 patients who completed CAPACITY. PIPF-002 is an on-going long-term, open-label study in 83 IPF patients.

The summary and conclusions from the safety analysis as presented at ERS were:

  • A comprehensive review of safety data from four clinical studies showed that treatment with pirfenidone was safe and generally well tolerated
  • In the CAPACITY studies:
  • The majority of adverse events (AE) were mild to moderate in nature and relatively few patients discontinued treatment due to adverse events.
  • A similar incidence of serious adverse events (SAE) was observed in the pirfenidone group relative to the placebo group
  • Fewer deaths were observed in the pirfenidone group relative to the placebo group and this difference was driven by a reduction in IPF-related deaths
  • GI and skin AE were more common in pirfenidone-treated patients and were generally mild to moderate, transient, and rarely led to treatment discontinuation
  • Transaminase (liver enzyme) elevations were slightly more common in the pirfenidone group, generally low-grade and without clinical sequ
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the ... received a Canadian Patent for Inhibition or Reversal ... includes claims using thymosin beta 4, various fragments ... these purposes.  The patent will expire in 2021. ... www.regenerx.com ) RegeneRx is focused ...
(Date:9/30/2014)... Hungary , September 30, 2014 ... and intuitive browsing of chemistry in documents ... chemistry software solutions and consulting services for life ... chemical information and generate Markush structures from documents. ... an organizations intellectual property, however generating and understanding ...
(Date:9/30/2014)... OriginOil Inc. (OTC/QB: OOIL), developer of Electro ... up large quantities of water, announced today that in ... the launch of the company's CLEAN-FRACâ„¢ industrial grade demonstrator ... STW Resources . , Immediately upon startup, the ... and achieved a 99.8% reduction in Turbidity on flowback ...
(Date:9/30/2014)... Md., Sept. 30, 2014 BioHealth Innovation, ... commercializing market-relevant biohealth innovations and increasing access to early-stage ... today that venture capitalist, Tania Fernandez , Ph.D., ... Dr. Fernandez will be a member of the management ... provide up to $50 million in seed and early-stage ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... , ... , , , Antibodies ... arrays) or as biopharmaceutical therapeutics. In,all cases the successful production ... criteria include: protein identification,quantitation and the monitoring of purity and ...
... , ... , , , ... of the Agilent 2100 bioanalyzer in combination,with the Protein 200 Plus ... denaturing gel-elctrophoresis (SDSPAGE).,The results showed that the Agilent 2100 bioanalyzer provides,fast ...
... , ... , , , , ... an siRNA sequence,for a target gene, which are of,high importance ... crucial.,An efficient method to optimize,transfection and gene silencing,is critical for ...
Cached Biology Technology:Quality control of antibodies using the,2100 bioanalyzer and the Protein 200,Plus assay 2Quality control of antibodies using the,2100 bioanalyzer and the Protein 200,Plus assay 3Comparison of different protein,quantitation methods 2Comparison of different protein,quantitation methods 3Comparison of different protein,quantitation methods 4Comparison of different protein,quantitation methods 5Comparison of different protein,quantitation methods 6Comparison of different protein,quantitation methods 7Comparison of different protein,quantitation methods 8Comparison of different protein,quantitation methods 9Confirming gene silencing,mechanism by pGFP/GFP22 ,siRNA co-transfection 2Confirming gene silencing,mechanism by pGFP/GFP22 ,siRNA co-transfection 3Confirming gene silencing,mechanism by pGFP/GFP22 ,siRNA co-transfection 4
(Date:9/30/2014)... Salk professor and Howard Hughes Medical Institute investigator, ... named recipients in the 2014 round of grants ... the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) ... announced September 30, provides more than $3 million ... years. , The BRAIN Initiative, launched last year, ...
(Date:9/30/2014)... water may increase the risk of stillbirth and ... by a Boston University School of Public Health ... Environmental Health , compared 1,091 PCE-exposed pregnancies ... Cape Cod, Ma., where water was contaminated in ... the installation of vinyl-lined asbestos cement pipes. PCE ...
(Date:9/30/2014)... live in almost any aquatic environment on Earth, but ... species are pushed to the limit. The amount of ... critical for how different species cope in the future, ... of Gothenburg, published in the scientific journal Proceedings ... continues apace thanks to increasing levels of greenhouse gases ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2Contaminated water linked to pregnancy complications, BU study finds 2Shape up quickly -- applies to fish, too! 2
... in ecological or environmental conservation remains contentious the ... demand that governments regulate and encourage restoration projects; ... corporations makes such interventions politically difficult. However, ... a handful of developing nations, alongside South Africa, ...
... , RIVERSIDE, Calif. Alan McHughen , a ... University of California, Riverside, has been chosen by the ... Sciences to receive a 2011-2012 Jefferson Science Fellowship ... selected for the fellowships this year. Successful ...
... is redefining the rules by which we live and at ... level, several areas of the globe are in danger of ... and maybe, one day, live in floating houses. Depending ... others in their adjustment to the effects of global warming, ...
Cached Biology News:UC Riverside plant biotechnologist receives prestigious Jefferson Science Fellowship 2UC Riverside plant biotechnologist receives prestigious Jefferson Science Fellowship 3Floating houses 2Floating houses 3
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... 20-HETE is a cytochrome P450 (CYP450) metabolite ... the renal and cerebral vasculature. In rat ... mediates pressure-induced autoregulatory vasoconstriction. 20-HETE is excreted ... of free 20-HETE (20-40 pg/ml in human ...
... GPS-M Mutagenesis System enables you to insert ... into,your target DNA by in vitro transposition. ... Tn7-based,transposon randomly into the DNA target. Target ... or purified,chromosomal DNA, depending on your interests ...
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: